Generic phenytoin
Executive Summary
FDA's Generic Drugs Advisory Committee will discuss "issues on bioequivalence related to narrow therapeutic range drugs such as phenytoin" during its Feb. 10-12 meeting. FDA's request for advice from the committee on the anticonvulsant is precipitated in part by Warner-Lambert's recent manufacturing difficulties with its Dilantin Kapseal product and the lack of a generic slow-release or controlled-release version. FDA met with the company on Jan. 11 to discuss reformulation of the brandname product. The advisory committee meeting begins 8 a.m. at the Holiday Inn in Silver Spring, Md.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth